Trial Profile
Observational Study of the Effectiveness and Safety of Vismodegib (Erivedge) in Patients Treated in Argentina
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2018
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- Sponsors Roche
- 22 Feb 2018 Status changed from recruiting to completed.
- 30 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
- 30 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.